文献速递糖尿病

联合抑制胰高血糖素与肝优先胰岛素治疗糖尿病的临床前探索:基于体外实验及大鼠和小鼠模型

Preclinical exploration of combined glucagon inhibition and liver-preferential insulin for treatment of diabetes using in vitro assays and rat and mouse models.
PubMed 文献 · Diabetologia · 2022-11-21

研究设计了一种兼具胰高血糖素受体抑制与肝优先胰岛素作用的双效分子,在大鼠和小鼠模型中评估其药代动力学与药效学。该分子使糖尿病模型血糖正常化,低血糖倾向低于常规胰岛素,但肝甘油三酯、血浆丙氨酸氨基转移酶和α细胞质量仍升高。

要点

  • 双效分子使糖尿病模型血糖正常化,低血糖诱导效力约为血糖正常条件下的4.6分之一。
  • 较常规长效胰岛素,双效分子使肝甘油三酯升高约60%、血浆丙氨酸氨基转移酶升高约两倍、α细胞质量增加约两倍。
  • 在药理学相关剂量范围内,双效分子仍存在潜在安全性担忧。

核心结论

  • 双效胰高血糖素受体抑制剂与肝优先胰岛素分子显著改善血糖调控,但在药理学相关剂量范围内潜在安全性担忧持续存在。

研究设计与样本

  • 设计双效胰高血糖素受体抑制剂与肝优先胰岛素分子,在正常大鼠、链脲佐菌素诱导高血糖大鼠、db/db小鼠及饮食诱导肥胖联合链脲佐菌素诱导高血糖小鼠中测试。
  • 对双效分子及相关对照化合物进行药代动力学和药效学详细表征,并探索双效分子对胰高血糖素诱导恢复及急性低血糖自发恢复的影响。

主要发现

  • 双效分子使糖尿病模型血糖正常化。
  • 双效分子在低血糖条件下诱导低血糖的效力约比血糖正常条件下低4.6倍。
  • 与常规长效胰岛素治疗相比,双效分子使肝甘油三酯水平升高约60%。
  • 与常规长效胰岛素治疗相比,双效分子使血浆丙氨酸氨基转移酶水平升高约两倍。
  • 与常规长效胰岛素治疗相比,双效分子使α细胞质量增加约两倍。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Normalisation of blood glucose in individuals with diabetes is recommended to reduce development of diabetic complications. However, risk of severe hypoglycaemia with intensive insulin therapy is a major obstacle that prevents many individuals with diabetes from obtaining the recommended reduction in HbA1c. Inhibition of glucagon receptor signalling and liver-preferential insulin action have been shown individually to have beneficial effects in preclinical models and individuals with diabetes (i.e. improved glycaemic control), but also have effects that are potential safety risks (i.e. alpha cell hyperplasia in response to glucagon receptor antagonists and increased levels of liver triacylglycerols and plasma alanine aminotransferase activity in response to glucagon receptor antagonists and liver-preferential insulin). We hypothesised that a combination of glucagon inhibition and liver-preferential insulin action in a dual-acting molecule would widen the therapeutic window. By correcting two pathogenic mechanisms (dysregulated glucagon signalling and non-physiological distribution of conventional insulin administered s.c.), we hypothesised that lower doses of each component would be required to obtain sufficient reduction of hyperglycaemia, and that the undesirable effects that have previously been observed for monotreatment with glucagon antagonists and liver-preferential insulin could be avoided. METHODS: A dual-acting glucagon receptor inhibitor and liver-preferential insulin molecule was designed and tested in rodent models (normal rats, rats with streptozotocin-induced hyperglycaemia, db/db mice and mice with diet-induced obesity and streptozotocin-induced hyperglycaemia), allowing detailed characterisation of the pharmacokinetic and pharmacodynamic properties of the dual-acting molecule and relevant control compounds, as well as exploration of how the dual-acting molecule influenced glucagon-induced recovery and spontaneous recovery from acute hypoglycaemia. RESULTS: This molecule normalised blood glucose in diabetic models, and was markedly less prone to induce hypoglycaemia than conventional insulin treatment (approximately 4.6-fold less potent under hypoglycaemic conditions than under normoglycaemic conditions). However, compared to treatment with conventional long-acting insulin, this dual-acting molecule also increased triacylglycerol levels in the liver (approximately 60%), plasma alanine aminotransferase levels (approximately twofold) and alpha cell mass (approximately twofold). CONCLUSIONS/INTERPRETATION: While the dual-acting glucagon receptor inhibitor and liver-preferential insulin molecule showed markedly improved regulation of blood glucose, effects that are potential safety concerns persisted in the pharmacologically relevant dose range.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Hvid H, Brand CL, Hummelshøj T, et al. Preclinical exploration of combined glucagon inhibition and liver-preferential insulin for treatment of diabetes using in vitro assays and rat and mouse models. Diabetologia. 2022. PMID: 36404376. doi:10.1007/s00125-022-05828-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。